Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

Inclusion Criteria: * Histologically confirmed, potentially resectable rectal adenocarcinoma staged as uT3/4 N0/1 by endosonography or cT3/4 by MRI of the pelvis with or without local lymph node metastases. * Wild-type KRAS. * ECOG-performance status 0 or 1. * Age ≥ 18 years. * Laboratory requirements: * Haematology: Leucocyte count \> 3,000/mm³, neutrophil count ≥1.5x109/L, hemoglobin ≥ 8 g/dL, platelet count ≥100x109/L. * Hepatic Function: Total bilirubin ≤ 1.5 time the upper normal limit (UNL), ASAT ≤ 2.5xUNL in absence of liver metastases or ≤ 5xUNL in presence of liver metastases, ALAT ≤ 2.5xUNL in absence of liver metastases or ≤ 5xUNL in presence of liver metastases * Renal Function: Creatinine clearance ≥50 mL/min or serum creatinine ≤1.5xUNL * Metabolic Function: Magnesium ≥ lower limit of normal, Calcium ≥ lower limit of normal. * Negative ß-HCG-serum pregnancy test (females of child bearing potential). * Willing to use double-barrier contraception during study and for 6 months after the end of treatment. * Ability of patient to understand character and individual consequences of clinical trial * Written informed consent (must be available before enrollment in the trial) Exclusion Criteria: * Prior EGFR targeting or prior chemo- or radiotherapy or tumor surgery. * Evidence of any distant metastases. * Manifest or previous secondary malignancies within the last 5 years. * Uncontrolled infection. * Clinically significant cardiovascular disease NYHA classification III or IV (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrollment/randomization. * History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on screening chest CT scan. * Diabetes mellitus * Subject pregnant or breast feeding, or planning to become pregnant within 6 month after the end of treatment. * Subject (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 6 months (male or female) after the end of treatment. * Active serious illness which renders the patient unsuitable for study entrance, multiple blood sampling or the above mentioned biopsies. * History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product. * Participation in other clinical trials or observation period of competing trials, respectively.